Back to full portfolio

Bicara

IPO - BCAX

Oncology therapeutics company developing novel bifunctional antibodies for treatment of solid tumors.
WEBSITE
“Premji Invest has been an early supporter of Bicara from the beginning, having participated in both our Series A and Series B financing. With their support, Bicara is moving forward with urgency towards delivering potential new treatment options to patients struggling with head and neck cancers.”
Claire Mazumdar
CEO, Bicara Therapeutics Inc.
Claire Mazumdar
Founder(s)
Claire Mazumdar
THEME(S)
No items found.
SECTOR(S)
Healthcare
Investment Stage
Early
Company Status
IPO/Public
BicaraPlay Icon

Perspectives

More about Bicara

Bicara Therapeutics
Perspectives

Updated Interim Phase 1/1b Data of Ficerafusp Alfa (BCA101) in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

June 1, 2024
Read more
Bicara Therapeutics
Bicara Therapeutics

Updated Interim Phase 1/1b Data of Ficerafusp Alfa (BCA101) in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Read more